Ultivue Announces New Innovation Team Leadership
5.4.2022 17:00:00 EEST | Business Wire | Press release
Ultivue is thrilled to announce the addition of Professor Je Hyuk Lee in the role of Director of Research and Innovation, as the company adds to its growing expertise in spatial biology.
Je Lee is a highly published MD/PhD with over 25 years of scientific experience, most recently leading a successful research group at Cold Spring Harbor Laboratories (CSHL) that focused on innovative imaging and molecular sequencing methods for tracking genes, molecules, and cells to understand how cancer cells arise and evolve. Prior to his tenure at CSHL, Je was at scientist at the Wyss Institute for Biologically Inspired Engineering in Boston and spent many years as a postdoctoral research fellow under Professor George Church at Harvard Medical School, Boston where his highly cited work on the generation and in situ sequencing of whole transcriptome libraries has been seminal to how we consider highly multiplexed and spatially resolved techniques today.
Je holds a BS. Biochemistry from University of Pennsylvania, Philadelphia and a MD, PhD in Cell & Molecular Physiology Tufts School of Medicine, Boston.
Je joins Ultivue after a successful 2021 year of funding and looks to help strengthen its position as a market leader affording innovative solutions for multiplex immunofluorescence and digital image analysis.
"Translating advances in spatial biology into a robust and scalable solution that meets the needs of clinicians and patients is a challenge. Ultivue scientists have developed a deceptively simple solution to that problem, and I look forward to leading the team toward a more practical yet information-rich tissue imaging platform in oncology and research." said Je Lee, adding that “Its exciting to be part of one of the top spatial biology companies in the world today, selected by GEN , a field that has made its way into the mainstream of science when it was unanimously recognized in January 2021 by editors of the Nature journal as Method of the Year 2020”.
“Je Lee is joining at a very exciting time as we continue to accelerate not only our growth in the immuno-oncology market but also how we evolve and think about the future of multi-omics applications, imaging, and the rich amount of information we can gather from spatial phenomics” noted Jacques Corriveau, President and CEO.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005340/en/
Contact information
Ultivue
Jacques Corriveau
President and CEO
Jacques.corriveau@ultivue.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer Named Top Vendor Law Firm SaaS Solution Provider in the DACH Region for 202720.7.2026 10:00:00 EEST | Press release
Wolters Kluwer’s Legal & Regulatory has been recognized as a top vendor for Law Firm SaaS Solutions in the DACH region for 2027, according to the latest Vendor Selection Matrix™ by Research in Action. Kleos, the company's cloud-native legal practice management platform, achieved a shared first-place position in the ranking and received the highest scores for customer satisfaction, value for money and customer recommendation among surveyed law firms in Germany, Austria and Switzerland. The recognition builds on the platform's earlier pan-European leadership position and reinforces Kleos' standing as one of Europe's leading legal practice management solutions. "We are proud to be recognized as a leading provider of Law Firm SaaS Solutions in the DACH region,” said Sergio Liscia, Vice President Legal Software at Wolters Kluwer. “What makes this recognition particularly meaningful is that it reflects the experience of legal professionals themselves. Achieving the highest ratings for custom
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 09:00:00 EEST | Press release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260719172592/en/ IQM's whitepaper on hybrid quantum optimization for railway scheduling, developed with Deutsche Bahn. Using a real operational dataset from Deutsche Bahn, a schedule of 190 trips across five German cities translating into roughly 98,500 possible cycles, the two organizations developed and tested a hybrid quantum-classical algorithm designed for enterprise-scale optimization problems. As detailed in a published whitepaper here, the IQM team applied the Quantum Approximate Optimization Algorithm (QAOA) in manageable stages, with the quantum component solving smaller subproblems within a classic
Galderma Launches Alastin ® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent launches in China and Australia and underscores Galderma’s continued investment in JPAC, a region characterized by advanced skincare practices and rapid growth in injectable aesthetics.1,2 This is increasing demand for integrated skincare solutions that support skin readiness, recovery and long-term quality.3,4,5 Alastin addresses this need through its range of peri-procedural support and daily skincare products that amplify the skin’s natural regenerative abilities, supporting recovery and enhances visible outcomes of in-demand aesthetic procedures such as energy-based device
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 20:10:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic cancer and colorectal cancer, our TGFβR2×PD-1 bispecific antibody in microsatellite stable colorectal cancer and our CDK2 inhibitor in recurrent epithelial ovarian cancer – investigational approaches that reflect our focus on areas where there is significant need for novel therapies." Details on key data presentations at ESMO include: Rapid Oral Presentations INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Mono
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 15:24:00 EEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom